New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 9, 2014
18:05 EDTTHRXTheravance study results confirm in vitro potency of VIBATIV
Theravance announced new data from multiple studies of VIBATIV. These study results, which offer new insight into the product's in vitro potency, efficacy and safety, will be the focus of multiple presentations over the next several days at the 24th European Congress of Clinical Microbiology and Infectious Diseases in Barcelona, Spain. Combined, the data presentations confirm the in vitro potency of VIBATIV and its efficacy in patients with complicated skin and skin structure infections including methicillin-resistant Staphylococcus aureus.
News For THRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2015
16:50 EDTTHRXTheravance sees results from Salford COPD lung study in 2016
"Results from the SUMMIT chronic obstructive pulmonary disease study of 16,000 patients evaluating the impact of Relvar/Breo Ellipta on all-cause mortality among patients with COPD who have cardiovascular disease are expected to be available by year-end 2015. The Salford lung study in COPD is expected to complete by the end of 2015 with the first results expected in 2016," said the company.
16:48 EDTTHRXTheravance reports Q2 EPS (7c), consensus (6c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use